Selim DERECİ, Bülent ZÜLFİKAR, Gül Nihal ÖZDEMİR, Serdar ÖZKASAP

Hemofili B hastası bir süt çocuğunun tedavisindeki zorluklar

Difficulties in the treatment of an Infant with Hemophilia B

PDF

___

1. Soucie JM, Jackson D, Evatt B. Occurrence of hemophilia in the United States: The Hemophilia Surveillance System Project Invest. Am J Hematol 1998; 59: 288-94. [CrossRef ]
2. Iorio A, Oliovecchio E, Morfini M, et al. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia 2008; 14: 444-53. [CrossRef ]
3. DiMichele DM. Inhibitor treatment in haemophilias A and B: Inhibitor diagnosis. Haemophilia 2006; 12: 37-41. [CrossRef ]
4. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138: 305-15. [CrossRef ]
5. Warrier I, Lusher JM. Development of anaphylactic shock in haemophilia B patients with inhibitors. Blood Coagul Fibrinolysis 1998; 9: 125-8.
6. Schoppmann A, Jaeger K, Berg R, et al. Review of the literature of feiba administration in patients with hemophilia B and inhibitors. J Coagul Disord 2011; 3: 14-26.
7. Ewenstein BM, Wong WY, Schoppmann A. Bleeding reduction during secondary prophylaxis with bypassing agents in inhibitor patients. Thromb Res 2011; 127: 174-5. [CrossRef ]
8. Zülfikar B, Kavaklı K, Antmen B, Atay A, Şalcıoğlu Z, Ar C. Hemostatic management of surgical procedures with Feiba: a Turkish case series. Haemophilia 2008; 14 (Suppl 2): 54-5.
9. Verma D, Moghimi B, LoDuca PA, Singh HD, Hoffman BE, Herzog RW, Daniell H. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc Natl Acad Sci U S A 2010; 13; 107: 7101-6. [CrossRef ]
10. Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19: 23-7. [CrossRef ]